Loading…
To establish the Adams Memorial Commission to carry out the provisions of Public Law 107-62, and for other purposes.
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
48pct
12d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
This bill amends the Act that authorized the Adams Memorial Foundation to establish a commemorative work in Washington, D.C., to honor John Adams and his legacy to, instead, establish the Adams Memorial Commission to establish a permanent memorial in Washington, D.C., for such purpose. The commission shall: (1) consider, formulate, and report plans for such memorial; and (2) terminate seven years after this bill's enactment.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2016 · fourth_quarter · Government Issues
Location and design of the Adams Family Memorial in Washington, D.C.; Establishment of a Presidential Commission for the Adams memorial (H.R. 5748).
Client expense: Not reported · Firm income: Not reported
Referred to the Subcommittee on Federal Lands.
Referred to the House Committee on Natural Resources.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Government Issues
Location and design of the Adams Family Memorial in Washington, D.C.; Establishment of a Presidential Commission for the Adams memorial (H.R. 5748).
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
Issues relating to prescription drug abuse; Issues relating to incentives for tamper-resistant formulations; H.R. 471 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Issues relating to the labeling of generic drugs; Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H.R. 106. Issues relating to bioequivalence and related administrative procedures; Issues relating to incentives for tamper-resistant formulation, Issues relating to Medicare Part D rebates; Issues relating to products containing high doses of acetaminophen. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to Opioids. H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Issues relating to prescription drug abuse; Issues relating to incentives for tamper-resistant formulations; H.R. 471 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Issues relating to the labeling of generic drugs; Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H.R. 106. Issues relating to bioequivalence and related administrative procedures; Issues relating to incentives for tamper-resistant formulation, Issues relating to Medicare Part D rebates; Issues relating to products containing high doses of acetaminophen. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to Opioids. H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Issues relating to prescription drug abuse; Issues relating to incentives for tamper-resistant formulations; H.R. 471 Ensuring Patient Access and Effective Drug Enforcement Act of 2015; Issues relating to the labeling of generic drugs; Issues relating to eliminating Medicare coverage for prosthetic urological interventions, including H.R. 106. Issues relating to bioequivalence and related administrative procedures; Issues relating to incentives for tamper-resistant formulation, Issues relating to Medicare Part D rebates; Issues relating to products containing high doses of acetaminophen. Issues relating to FDA approvals of new drugs and generic drugs. Issues related to Opioids. H.R.471, S. 483 -Ensuring Patient Access and Effective Drug Enforcement Act of 2015. S. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| MA |
| Michael E. Capuano | Democratic | MA |
| Niki Tsongas | Democratic | MA |
| Richard E. Neal | Democratic | MA |
| Seth Moulton | Democratic | MA |
| Steve Chabot | Republican | OH |
| William R. Keating | Democratic | MA |